J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in

J&J’s third-line multiple myeloma blockbuster Darzalex got the FDA green light for a new regimen to take another swing at the blood cancer — this time, in a cocktail with carfilzomib and dexamethasone.